Why the study?
The prognostic significance of late gadolinium enhancement in pediatric HCM remained to be fully validated, particularly in an Asian population.
Does late gadolinium enhancement extent predict sudden cardiac death and heart failure events in pediatric hypertrophic cardiomyopathy?
Does late gadolinium enhancement extent predict sudden cardiac death and heart failure events in pediatric hypertrophic cardiomyopathy?
In a Chinese pediatric HCM cohort, late gadolinium enhancement extent was independently associated with adverse outcomes and improved sudden cardiac death risk stratification models.
May refine SCD risk models in pediatric HCM without changing practice; extends Western LGE data to Asians but leaves open prospective validation.
Background: Recently, late gadolinium enhancement (LGE) has been identified as an important risk factor in pediatric hypertrophic cardiomyopathy (HCM). However, its prognostic significance in pediatric HCM remains to be fully validated, particularly in Asian population. This study aims to assess the prognostic value of LGE and explore its incremental utility in predicting sudden cardiac death (SCD) in pediatric HCM using data from a Chinese cohort. Methods: 231 primary HCM patients ≤18 years of age with cardiac magnetic resonance (CMR) were retrospectively and consecutively enrolled in a single center. The composite outcomes included SCD or equivalent events and heart failure-related events. Findings: Of 231 patients (median age 15, IQR: 12-16), LGE was present in 195 (84.4%) with a median LGE extent of 4.7% (IQR: 2.0%-9.2%). During a median follow-up of 62 months (IQR: 39-85), 26 (11.3%) patients reached composite outcomes, and 13 (5.6%) patients experienced SCD events. Kaplan-Meier analysis showed a significantly increased risk of composite outcomes (log-rank P < 0.001) and SCD (log-rank P < 0.001) in the group with LGE extent ≥5%. In multivariable Cox analysis adjusted by clinical and imaging factors, LGE extent was independently associated with composite outcomes (adjusted HR: 1.15; P < 0.001) and SCD (adjusted HR: 1.11; P = 0.009). For SCD events, the addition of LGE extent could improve the model performance of HCM Risk-Kids model (C-statistics: 0.65 versus 0.79, P = 0.015) and PRIMaCY model (C-statistics: 0.62 versus 0.82, P = 0.002), respectively. Interpretation: In Chinese pediatric HCM, LGE serves as a risk factor in predicting adverse outcomes and may enhance SCD risk stratification strategies. Funding: This study was funded by the National Key Research and Development Program of China (2021YFF0501400 and 2021YFF0501404), the Key Project of the National Natural Science Foundation of China (82430066), and the Yunnan Province Science and Technology Platform and Talent Project (202305AF150033).
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: